3.79 USD
↗ 0.00 (0.00%)AT CLOSE (03:59 PM EDT)
Aclaris Therapeutics, Inc.
ACRSNASDAQ • USD
3.68
↘ 0.12 (3.03%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
3.68
↘ 0.12 (3.03%)
Market: CLOSED
ACRS is currently priced at $3.78. Our models show a "Neutral" technical signal alongside a "Sell" fundamental rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, ACRS is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Oct 27, 2026.
Open?$3.98
High?$4.00
Low?$3.44
Prev. Close?$3.79
Volume?8.0M
Avg. Volume?3.8M
VWAP?$3.68
Rel. Volume?2.12x
Bid / Ask
Bid?$3.44 × 100
Ask?$3.88 × 30.0K
Spread?$0.44
Midpoint?$3.66
Valuation & Ratios
Market Cap?557.9M
Shares Out?139.8M
Float?121.5M
Float %?86.9%
P/E Ratio?N/A
P/B Ratio?4.48
EPS?-$0.51
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Employees
73
Market Cap
557.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-10-07
Address
701 LEE ROAD
WAYNE, PA 19087
Phone: 484-324-7933
WAYNE, PA 19087
Phone: 484-324-7933
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?0
Momentum?57
Short Sent.?76
Piotroski F-Score?1/9Weak
Altman Z-Score?-2.86Distress
Confidence?53%Low
Short InterestHigh
Short % of Float?12.37%High
Short Interest?15.0M
Days to Cover?3.0
Free Float121.5M
Avg Daily Volume5.1M
Settlement Date2026-10-15
Financial Health
Current Ratio?3.46Strong
Quick Ratio?3.46Strong
Cash Ratio?0.68Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?4.48FAIR▾
Peers100
S&P40
P/S?67.88HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-6.3CHEAP▾
S&P97
EV/Sales?65.55HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-60.8%WEAK▾
S&P3
ROA?-42.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-62177000
Enterprise Value?$538.7M
Fundamentals ratios updated end of day